← Back to Search

Financial Incentives for Glaucoma Care Adherence

N/A
Waitlist Available
Led By Christopher A Girkin, MD, MSPH
Research Sponsored by University of Alabama at Birmingham
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Anyone ≥ 18 years with a glaucoma associated diagnosis
Non-Hispanic white ≥50 years
Timeline
Screening 3 weeks
Treatment Varies
Follow Up the time frame will be from baseline through 3 years of recruitment in the study.
Awards & highlights

Summary

This trial is testing a new way to detect and manage glaucoma, using telemedicine to improve access to care for a vulnerable population.

Who is the study for?
This trial is for adults over 18 with glaucoma-related diagnoses, diabetes, or a family history of glaucoma. It focuses on African Americans and Hispanics over 40, and non-Hispanic whites over 50. Participants must speak and understand English. There are no specific exclusion criteria.
What is being tested?
The study is testing if giving people money can make them more likely to go to eye care appointments after being referred for conditions like cataract, glaucoma, diabetic retinopathy, etc., compared to not offering money.
What are the potential side effects?
Since this trial involves financial incentives rather than medical treatments or drugs, there are no direct physical side effects associated with the interventions being tested.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 or older and have been diagnosed with glaucoma.
Select...
I am a non-Hispanic white person aged 50 or older.
Select...
I am 18 or older and have diabetes.
Select...
I can speak and understand English.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~the time frame will be from baseline through 3 years of recruitment in the study.
This trial's timeline: 3 weeks for screening, Varies for treatment, and the time frame will be from baseline through 3 years of recruitment in the study. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Percentage of participants that adhere to referral appointment

Trial Design

2Treatment groups
Experimental Treatment
Group I: No financial incentiveExperimental Treatment1 Intervention
This group will receive standard of care eye health education alone and no financial incentive for completing a referral visit.
Group II: Financial incentiveExperimental Treatment1 Intervention
This group will receive a financial incentive once the referral visit is completed (if one was required) as well as eye health education.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Financial Incentive
2016
N/A
~133420

Find a Location

Who is running the clinical trial?

Centers for Disease Control and PreventionFED
882 Previous Clinical Trials
22,473,985 Total Patients Enrolled
University of Alabama at BirminghamLead Sponsor
1,621 Previous Clinical Trials
2,289,978 Total Patients Enrolled
3 Trials studying Refractive Errors
440 Patients Enrolled for Refractive Errors
Christopher A Girkin, MD, MSPHPrincipal InvestigatorUniversity of Alabama at Birmingham

Media Library

Financial Incentive Clinical Trial Eligibility Overview. Trial Name: NCT04328207 — N/A
Refractive Errors Research Study Groups: No financial incentive, Financial incentive
Refractive Errors Clinical Trial 2023: Financial Incentive Highlights & Side Effects. Trial Name: NCT04328207 — N/A
Financial Incentive 2023 Treatment Timeline for Medical Study. Trial Name: NCT04328207 — N/A
~207 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top